Phosphatidylserine

Pharmacology & Research

Phosphatidylserine (PS) is an aminophospholipid that sits on the inner leaflet of neuronal cell membranes, where it supports membrane fluidity, ion-pump activity and neurotransmitter release. The evidence posture is best described as “old positive data, newer flat data”: the pivotal memory and stress trials of the 1980s–90s used bovine-cortex PS (BC-PS), which is no longer sold because of prion (BSE) risk, and the soy- and sunflower-derived PS on shelves today has not cleanly reproduced those benefits. The strongest signal remains age-related memory complaints and childhood ADHD — but effects are modest, most trials are small or industry-linked, and much of the benefit concentrates in people who start out impaired rather than healthy adults seeking a cognitive edge. Because the brain synthesises PS endogenously, this is a case of supplementing on top of adequacy rather than correcting a dietary deficiency, so the burden of proof for a real effect is high. The U.S. FDA allows only a qualified health claim, explicitly stating that the supporting science is very limited and largely inconclusive.

0. Evidence by application

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

Application	Support	Rests on
Age-related memory decline	██████░░░░ 64%	Several RCTs (n=120–494); strongest with bovine PS, mixed with soy PS
ADHD in children	██████░░░░ 58%	2 small RCTs + a systematic review/meta-analysis; short, small
Stress & cortisol response	█████░░░░░ 53%	Small human trials; robust with high-dose bovine PS, weaker orally
Alzheimer’s & dementia treatment	█████░░░░░ 46%	1980s–90s RCTs; short-lived, non-disease-modifying
Exercise capacity & recovery	████░░░░░░ 40%	Small crossover trials; capacity signal, cortisol equivocal
Healthy adult cognition	███░░░░░░░ 32%	1–2 small acute trials; mostly manufacturer-run

1. Age-related memory decline

The best-known positive data come from bovine-cortex PS: Crook et al. treated 149 people with age-associated memory impairment (AAMI) with 300 mg/day for 12 weeks and saw improvement on learning and daily-memory tasks, concentrated in those who started out most impaired ^{1Reference 1Crook et al. · 1991RCTEffects of phosphatidylserine in age-associated memory impairment — [RCT]View study →}. Cenacchi et al. ran a larger 6-month multicentre trial in 494 elderly patients (300 mg/day) and reported benefit on behavioural and cognitive measures ^{2Reference 2Cenacchi et al. · 1993RCTCognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration — [RCT]View study →}. The catch: when the same 300 mg/day design was repeated with soy-derived PS in 120 AAMI subjects, it did not significantly outperform placebo ^{3Reference 3Jorissen et al. · 2001The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment — [controlled trial, null]View study →}. Later soy-PS work (e.g. 100–300 mg/day in Japanese elderly with memory complaints) reported gains but often without a clear placebo separation ^{4Reference 4Kato-Kataoka et al. · 2010Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints — [trial]View study →}, and a 2010 RCT of PS conjugated to omega-3 (PS-DHA, 300 mg/day, 15 weeks) improved memory only in a more-impaired subgroup ^{5,6Reference 5Vakhapova et al. · 2010RCTPhosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints — [RCT]View study →Reference 6Vakhapova et al. · 2014RCTPhosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly: open-label extension — [RCT extension]View study →}. More recently, a 2025 double-blind RCT of a PS-containing food supplement in Chinese older adults with mild cognitive impairment reported improved cognitive scores versus placebo ^{22Reference 22Zhang et al. · 2025RCTEffects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: a randomized double-blind, placebo-controlled trial — [RCT]View study →} — a rare modern positive signal, though it tested a multi-ingredient supplement rather than PS alone.

Gap: the pivotal benefit was shown with a source (bovine cortex) that is no longer sold; modern soy/sunflower PS has weaker and less consistent support.

2. ADHD in children

Hirayama et al. gave 200 mg/day soy-PS to 36 children (4–14 y) for 2 months and reported significant improvement in ADHD symptoms and short-term auditory memory, with no adverse effects ^{7Reference 7Hirayama et al. · 2014RCTThe effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder — [RCT]View study →}. A larger trial of PS conjugated to omega-3 (PS-Omega3) in 200 children showed benefit mainly in a hyperactive-impulsive, emotionally dysregulated subgroup during the double-blind phase, with broader gains during open-label extension ^{8Reference 8Manor et al. · 2012RCTThe effect of phosphatidylserine containing omega-3 fatty acids on ADHD symptoms in children — [RCT with open-label extension]View study →}. An earlier RCT of n-3 fatty acids delivered as phospholipids in inattentive children also linked improved blood fatty-acid status to better visual sustained attention ^{20Reference 20Vaisman et al. · 2008RCTCorrelation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n−3 fatty acids containing phospholipids — [RCT]View study →}, consistent with the omega-3-conjugated results. A 2021 systematic review and meta-analysis concluded that PS produced a small, statistically detectable reduction in ADHD symptoms but flagged the small number of trials, small samples, and short duration as limiting confidence ^{9Reference 9Bruton et al. · 2021Meta-analysisPhosphatidylserine for the treatment of pediatric attention-deficit/hyperactivity disorder: a systematic review and meta-analysis — [meta-analysis]View study →}.

Gap: only a handful of small, short RCTs — some manufacturer-funded — and the omega-3 co-formulation makes it hard to isolate PS’s own contribution.

3. Stress & cortisol response

High-dose PS blunts the neuroendocrine stress response. Monteleone et al. showed that intravenous bovine PS (50–75 mg) reduced the ACTH and cortisol rise after exercise ^{10Reference 10Monteleone et al. · 1990Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans — [controlled trial]View study →}, and that 800 mg/day orally for 10 days blunted the ACTH/cortisol response to physical stress in healthy men ^{11Reference 11Monteleone et al. · 1992Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men — [controlled trial]View study →}. Oral results at lower, supplement-realistic doses are weaker and dose-dependent: 600 mg/day attenuated cortisol in one exercise study ^{12Reference 12Starks et al. · 2008RCTThe effects of phosphatidylserine on endocrine response to moderate intensity exercise — [RCT]View study →}, while other trials at 300–750 mg/day found effects on mood or capacity but not a clear cortisol change ^{13,18,21Reference 13Kingsley et al. · 2006RCTEffects of phosphatidylserine on exercise capacity during cycling in active males — [RCT]View study →Reference 18Parker et al. · 2011RCTThe effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise — [RCT, industry]View study →Reference 21Benton et al. · 2001The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor — [trial]View study →}.

Gap: the clearest effects used high or intravenous doses of bovine PS; benefit at typical 100–300 mg/day oral soy-PS doses is inconsistent.

4. Alzheimer’s & dementia treatment

Several 1980s–90s double-blind trials of bovine PS (usually 300 mg/day) in Alzheimer’s and senile dementia reported short-term improvement on cognitive and behavioural scales, most apparent in milder cases ^{14,15,16Reference 14Delwaide et al. · 1986RCTDouble-blind randomized controlled study of phosphatidylserine in senile demented patients — [RCT]View study →Reference 15Engel et al. · 1992RCTDouble-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type — [RCT]View study →Reference 16Amaducci · 1988RCTPhosphatidylserine in the treatment of Alzheimer’s disease: results of a multicenter study — [RCT]View study →}. These effects were modest and tended to fade over months, and PS is not disease-modifying — it does not alter the underlying course of Alzheimer’s.

Gap: short, dated trials with bovine PS; no evidence that modern PS treats or slows dementia, and the FDA health claim explicitly excludes a treatment claim.

5. Exercise capacity & recovery

Soy-PS at 750 mg/day for 10 days improved exercise capacity (time to exhaustion) in active men in a small crossover trial ^{13Reference 13Kingsley et al. · 2006RCTEffects of phosphatidylserine on exercise capacity during cycling in active males — [RCT]View study →} and altered markers of oxidative stress/soreness after intermittent running ^{17Reference 17Kingsley et al. · 2005RCTEffects of phosphatidylserine on oxidative stress following intermittent running — [RCT]View study →}. Endocrine effects across exercise studies are equivocal, and sample sizes are small (10–16 subjects).

Gap: small, short crossover studies with inconsistent endocrine findings; ergogenic benefit is not well established.

6. Healthy adult cognition

Evidence that PS sharpens cognition in healthy, non-impaired adults is thin. A manufacturer-run acute study reported faster processing speed and better accuracy after 400 mg PS before exercise ^{18Reference 18Parker et al. · 2011RCTThe effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise — [RCT, industry]View study →}, but replication in healthy people is limited, and a 2025 RCT of sunflower-PS in healthy children aged 8–12 showed only narrow cognitive effects ^{23Reference 23Research team · 2025RCTThe cognitive effects of supplementation with sunflower phosphatidylserine in healthy children aged 8 to 12 years: a randomized controlled trial — [RCT]View study →}.

Gap: almost no independent, adequately powered data in healthy adults; most positive signals come from impaired populations or industry studies.

Mechanisms

Target / pathway	Effect	Relevant to
Neuronal membrane phospholipid	Structural component; supports membrane fluidity	All cognitive applications
Na⁺/K⁺-ATPase	Upregulated (via PKC activation)	Neuronal excitability, memory
Acetylcholinesterase	Downregulated → higher synaptic acetylcholine (mostly aged-animal data)	Memory, ADHD
Protein kinase C (PKC)	Cofactor / activator	Signal transduction
Hypothalamic-pituitary-adrenal (HPA) axis	Blunts ACTH/cortisol rise to stress	Stress, cortisol
Acetylcholine / dopamine / noradrenaline release	Modulated	Cognition, mood

Pharmacokinetics

Oral PS is well absorbed (animal data suggest >90% bioavailability) and is lipophilic enough to cross the blood-brain barrier. It is incorporated into membranes or hydrolysed and re-synthesised; the serine head-group and fatty-acid tails are metabolised through normal lipid pathways. Plasma half-life is short (hours), but the relevant pharmacodynamic effect is membrane incorporation, not plasma level — so dosing is typically split (e.g. 100 mg three times daily). Bovine-cortex PS and soy/sunflower PS differ in their fatty-acid composition (bovine PS is richer in DHA-type long-chain fatty acids), which is one proposed reason the older bovine trials looked stronger; modern products are sometimes conjugated to DHA to mimic this. There is no established dietary deficiency state.

Clinical trials

PS has been studied in registered trials for cognitive decline, ADHD, and exercise performance, but it is an off-patent nutraceutical with limited large-scale industry-funded trial activity; most human data are small and older, and recent trials increasingly test PS combined with omega-3 or other nutrients rather than PS alone.

Completed	Planned	Terminated	Preclinical
~20 (mostly small)	few	few	~50+

Last checked: July 2026.

Dietary Sources

Phosphatidylserine is present in most foods but concentrated in a few. The body also synthesises it endogenously (by exchanging the head-group of phosphatidylcholine/ethanolamine for serine), so there is no dietary requirement and no deficiency state — dietary intake is a top-up, not a necessity. Average Western intake is estimated at roughly 75–185 mg/day.

Food	Approx. PS content
Bovine brain (historical; not recommended)	very high (~700+ mg/100 g)
Fish (mackerel, herring, eel)	moderate–high (~50–480 mg/100 g)
Organ meats (chicken/pork offal)	moderate
Soy lecithin	moderate (main commercial source)
White beans, egg	low–moderate
Dairy, most vegetables/fruit	low

Because organ and brain tissue are the richest natural sources and are no longer recommended for consumption (BSE and general food-safety reasons), commercial PS is now manufactured enzymatically from soy or sunflower lecithin. Intake estimates per Jäger et al. (2007) and the NIH ODS / IOM lipid references.

Dosage

• No RDA/AI and no Tolerable Upper Intake Level — PS is not an essential nutrient.
• Studied supplemental range: 100–300 mg/day for cognition (usually split, e.g. 100 mg three times daily), which is the standard label dose. Stress/exercise studies used 300–800 mg/day, and the strongest cortisol-blunting used 800 mg/day of bovine PS.
• Form matters more than dose here: the pivotal cognitive and stress trials used bovine-cortex PS, which is no longer sold. Modern soy- and sunflower-derived PS is what you can buy; it is safe and chemically similar but has weaker, less consistent efficacy data, partly because of a different fatty-acid profile. Some products conjugate PS to DHA (PS-omega-3) to mimic the bovine composition.
• Take with food (it is fat-soluble). Benefits in trials typically emerged over 6–12 weeks, not acutely.

Doses reflect ranges studied in research, not a personal recommendation.

Safety

PS has a good tolerability record. Soy-derived PS was formally shown to be safe at 200 and 300 mg/day for 12 weeks in elderly subjects, with no adverse effect on clinical chemistry, haematology or vital signs ^{19Reference 19Jorissen et al. · 2002Safety of soy-derived phosphatidylserine in elderly people — [safety study]View study →}, and cognition trials to 300 mg/day for 6 months reported no treatment-related harm ^{4Reference 4Kato-Kataoka et al. · 2010Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints — [trial]View study →}. The most common complaints are mild gastrointestinal upset and, occasionally, insomnia, more likely at higher doses (>300 mg/day) or when taken late in the day.

• Prion note: the historical safety concern was bovine-cortex PS (theoretical BSE/prion transmission). This is why the source switched; soy/sunflower PS carries no such risk.
• Blood thinners / anticoagulants: PS is often co-formulated with fish oil, which has antiplatelet effects — the combination could theoretically add to bleeding risk with warfarin/antiplatelet drugs. PS alone has no strong documented interaction.
• Cholinergic drugs: by raising acetylcholine, PS could in theory interact with anticholinergic or cholinergic medications (e.g. donepezil); this is mechanistic, not well documented clinically.
• Pediatric ADHD signal: an isolated 2025 case report described recurrent suicidality on rechallenge with a phosphatidylserine + citicoline product in a child with ADHD — a single anecdote, not established causation, but worth noting for pediatric use.

Pregnancy & lactation

Verdict: not established — avoid supplemental doses. There are no adequate trials of supplemental PS in pregnancy or lactation. Absence of reported harm is not evidence of safety; pregnant or breastfeeding people should not take PS supplements without clinician guidance.

Scope of this safety review (for honesty, not a claim):

• Interactions assessed? Partially — reviewed anticoagulant/antiplatelet (mainly via co-formulated fish oil) and cholinergic drug classes; no large formal interaction studies exist for PS alone.
• Pregnancy/lactation assessed? Yes — no adequate data found; treated as not established.
• Upper Limit? No UL set. This does not imply unlimited intake is safe; it reflects that no authority has evaluated one.

References

1. Crook, T. H., Tinklenberg, J., Yesavage, J., Petrie, W., Nunzi, M. G., & Massari, D. C. (1991). Effects of phosphatidylserine in age-associated memory impairment — [RCT]. Neurology. https://pubmed.ncbi.nlm.nih.gov/2027477/
2. Cenacchi, T., Bertoldin, T., Farina, C., Fiori, M. G., & Crepaldi, G. (1993). Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration — [RCT]. Aging (Milano). https://pubmed.ncbi.nlm.nih.gov/8323999/
3. Jorissen, B. L., Brouns, F., Van Boxtel, M. P. J., Ponds, R. W., Verhey, F. R., Jolles, J., & Riedel, W. J. (2001). The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment — [controlled trial, null]. Nutritional Neuroscience. https://pubmed.ncbi.nlm.nih.gov/11842880/
4. Kato-Kataoka, A., Sakai, M., Ebina, R., Nonaka, C., Asano, T., & Miyamori, T. (2010). Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints — [trial]. Journal of Clinical Biochemistry and Nutrition. https://pubmed.ncbi.nlm.nih.gov/21103034/
5. Vakhapova, V., Cohen, T., Richter, Y., Herzog, Y., & Korczyn, A. D. (2010). Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints — [RCT]. Dementia and Geriatric Cognitive Disorders. https://pubmed.ncbi.nlm.nih.gov/20523044/
6. Vakhapova, V., Richter, Y., Cohen, T., Herzog, Y., & Korczyn, A. D. (2014). Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly: open-label extension — [RCT extension]. Dementia and Geriatric Cognitive Disorders. https://pubmed.ncbi.nlm.nih.gov/24577097/
7. Hirayama, S., Terasawa, K., Rabeler, R., et al. (2014). The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder — [RCT]. Journal of Human Nutrition and Dietetics. https://pubmed.ncbi.nlm.nih.gov/23495677/
8. Manor, I., Magen, A., Keidar, D., et al. (2012). The effect of phosphatidylserine containing omega-3 fatty acids on ADHD symptoms in children — [RCT with open-label extension]. European Psychiatry. https://pubmed.ncbi.nlm.nih.gov/21807480/
9. Bruton, A., Nauman, J., Hanes, D. A., Gard, M., & Senders, A. (2021). Phosphatidylserine for the treatment of pediatric attention-deficit/hyperactivity disorder: a systematic review and meta-analysis — [meta-analysis]. Journal of Alternative and Complementary Medicine. https://pubmed.ncbi.nlm.nih.gov/33539192/
10. Monteleone, P., Beinat, L., Tanzillo, C., Maj, M., & Kemali, D. (1990). Effects of phosphatidylserine on the neuroendocrine response to physical stress in humans — [controlled trial]. Neuroendocrinology. https://pubmed.ncbi.nlm.nih.gov/2170852/
11. Monteleone, P., Maj, M., Beinat, L., Natale, M., & Kemali, D. (1992). Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men — [controlled trial]. European Journal of Clinical Pharmacology. https://pubmed.ncbi.nlm.nih.gov/1325348/
12. Starks, M. A., Starks, S. L., Kingsley, M., Purpura, M., & Jäger, R. (2008). The effects of phosphatidylserine on endocrine response to moderate intensity exercise — [RCT]. Journal of the International Society of Sports Nutrition. https://pubmed.ncbi.nlm.nih.gov/18662395/
13. Kingsley, M. I., Miller, M., Kilduff, L. P., McEneny, J., & Benton, D. (2006). Effects of phosphatidylserine on exercise capacity during cycling in active males — [RCT]. Medicine & Science in Sports & Exercise. https://pubmed.ncbi.nlm.nih.gov/16394955/
14. Delwaide, P. J., Gyselynck-Mambourg, A. M., Hurlet, A., & Ylieff, M. (1986). Double-blind randomized controlled study of phosphatidylserine in senile demented patients — [RCT]. Acta Neurologica Scandinavica. https://pubmed.ncbi.nlm.nih.gov/3518329/
15. Engel, R. R., Satzger, W., Günther, W., et al. (1992). Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type — [RCT]. European Neuropsychopharmacology. https://pubmed.ncbi.nlm.nih.gov/1633433/
16. Amaducci, L. (1988). Phosphatidylserine in the treatment of Alzheimer’s disease: results of a multicenter study — [RCT]. Psychopharmacology Bulletin. https://pubmed.ncbi.nlm.nih.gov/3290936/
17. Kingsley, M. I., Wadsworth, D., Kilduff, L. P., McEneny, J., & Benton, D. (2005). Effects of phosphatidylserine on oxidative stress following intermittent running — [RCT]. Medicine & Science in Sports & Exercise. https://pubmed.ncbi.nlm.nih.gov/16118575/
18. Parker, A. G., Gordon, J., Thornton, A., et al. (2011). The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise — [RCT, industry]. Journal of the International Society of Sports Nutrition. https://pubmed.ncbi.nlm.nih.gov/22017963/
19. Jorissen, B. L., Brouns, F., Van Boxtel, M. P. J., & Riedel, W. J. (2002). Safety of soy-derived phosphatidylserine in elderly people — [safety study]. Nutritional Neuroscience. https://pubmed.ncbi.nlm.nih.gov/12385596/
20. Vaisman, N., Kaysar, N., Zaruk-Adasha, Y., et al. (2008). Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n−3 fatty acids containing phospholipids — [RCT]. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/18469236/
21. Benton, D., Donohoe, R. T., Sillance, B., & Nabb, S. (2001). The influence of phosphatidylserine supplementation on mood and heart rate when faced with an acute stressor — [trial]. Nutritional Neuroscience. https://pubmed.ncbi.nlm.nih.gov/11842886/
22. Zhang, Y., et al. (2025). Effects of a food supplement containing phosphatidylserine on cognitive function in Chinese older adults with mild cognitive impairment: a randomized double-blind, placebo-controlled trial — [RCT]. Journal of Affective Disorders. https://pubmed.ncbi.nlm.nih.gov/39317299/
23. Research team (2025). The cognitive effects of supplementation with sunflower phosphatidylserine in healthy children aged 8 to 12 years: a randomized controlled trial — [RCT]. Nutrition Journal. https://pubmed.ncbi.nlm.nih.gov/41318468/